Surovatamig as Consolidation Therapy in Participants with Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma with Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

Trial Identifier: D7409C00001
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: April 2026
Primary Completion Date: November 2032
Study Completion Date: August 2033

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Adelaide, AU, 5000
AU Fitzroy, AU, 3065
AU Nedlands, AU, 6009
CA, AB Calgary, AB, CA, T2N 5G2
CA, Ontario Hamilton, Ontario, CA, L8V 5C2
CA, Quebec Montréal, Quebec, CA, H3T 1E2
GB Edinburgh, GB, EH4 2XU
GB Leeds, GB, LS9 7TF
GB London, GB, SE5 9RS
GB Oxford, GB, OX3 7LE
GB Sutton, GB, SM2 5PT
TR İstanbul, TR, 34899
TR Mezitli, TR, 33200